Skip to content
DataLookout
Menu

NCT07682870

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Start date changed from estimate of Sep 4, 2026 to Nov 11, 2026
  2. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Primary endpoints: details revised at 1 of 2 entries
    • Interventions: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection (Drug) to Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection (Drug)
    • Site details revised
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety:Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: 12 months
MTD/RP2D
Timeframe: During the 28 day DLT observation period

Secondary (8)

Level of deoxyribonucleic acid (DNA)
Interleukin level
ORR
Duration of relief(DOR)
DCR
Show 3 moreShow less
PFS
Immunogenicity Parameters
Efficacy and Safety of VG2025 and Its Correlation with CEA Levels

Arms and interventions

3+3 designExperimental

This is an open label, single-arm trial using standard 3+3 design, in up to 42 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients

Drugs: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

Sites

1 site in 1 country

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, China